Sequencing is the engine of modern biology, and the market that supplies it has become far more competitive and more interesting than it was a decade ago. A long-dominant incumbent now faces real challengers, single-cell and spatial technologies have opened entirely new experimental frontiers, and prices continue to fall. Here is a guide to the companies that matter and how to think about choosing a platform.
The sequencing platforms
- Illumina remains the dominant force in short-read sequencing, with the broadest installed base, the deepest ecosystem of protocols and applications, and platforms spanning benchtop instruments to enormous production sequencers. For most labs, it remains the default, and its ecosystem depth is a genuine advantage.
- Oxford Nanopore pioneered long-read, real-time sequencing on devices ranging from a pocket-sized sequencer to production-scale systems, with distinctive strengths in read length, portability, and direct detection of base modifications.
- PacBio offers highly accurate long reads that have become important for genome assembly, structural variant detection, and applications where short reads struggle.
- Element Biosciences, Ultima Genomics, and Singular Genomics emerged as credible challengers competing on cost per genome, throughput, and flexibility, and their presence has genuinely changed the competitive dynamic.
- MGI, part of the BGI group, is a major global supplier, though Western institutions weigh the evolving US policy environment around certain Chinese providers.
Single-cell and spatial biology
The most scientifically exciting frontier is the ability to measure biology one cell at a time and in spatial context, and a distinct set of companies leads here.
- 10x Genomics is the established leader in single-cell analysis, with a broad platform spanning single-cell gene expression, immune profiling, and spatial approaches, and its ecosystem is deeply embedded in academic and pharma research.
- Standard BioTools (formerly Fluidigm, now combined with SomaLogic) offers established single-cell and proteomics capabilities.
- NanoString pioneered spatial profiling, and Akoya Biosciences and Vizgen compete in spatial biology with distinct approaches to mapping molecules within intact tissue.
- Parse Biosciences and Scale Biosciences offer combinatorial-barcoding approaches that avoid specialized instruments, an appealing option for labs wanting single-cell capability without a large capital purchase.
What is driving the market
Three forces shape decisions right now. Cost per sample keeps falling, which expands what is experimentally possible and makes larger studies feasible. Competition has intensified, ending the era of a single unchallenged incumbent and giving buyers real leverage and choice. And the bottleneck has shifted from generating data to analyzing it, since a single-cell or spatial experiment produces enormous, complex datasets, meaning the informatics, software, and analytical support a vendor provides now matter as much as the instrument itself.
How to choose a platform
Let the science lead. Start with the biological question, since the right technology follows from what you actually need to measure, whether that is short-read depth, long-read structural resolution, single-cell resolution, or spatial context. Consider the full cost, not just the instrument: consumables and reagents typically dominate long-run spending, and vendor lock-in is real. Weigh ecosystem and support, including protocols, applications, and the analytical tools available, since a platform is only as useful as your ability to run and interpret it. Assess your informatics capacity honestly, because generating data you cannot analyze is a common and expensive trap. And consider throughput and flexibility against how your needs may change.
The bottom line
The sequencing and single-cell market in 2026 gives researchers more genuine choice than ever, with Illumina still dominant but meaningfully challenged by Oxford Nanopore, PacBio, and a wave of cost-focused newcomers, and with 10x Genomics leading a vibrant single-cell and spatial field. The right platform depends on your biological question, your budget across the full consumable lifecycle, your informatics capability, and the ecosystem you need around the instrument. Choose based on the science you want to do rather than the specifications you can boast about, and pay as much attention to analysis as to data generation, because that is where most projects now get stuck.
The analysis bottleneck is the real constraint
The most important practical shift in genomics over the past several years is that generating data has become far easier than making sense of it, and any lab planning a sequencing or single-cell program should design around that reality from the start. A single-cell or spatial experiment can produce enormous, complex, high-dimensional datasets, and the skills, compute, and time required to analyze them properly are substantial and frequently underestimated. Labs routinely generate data they lack the capacity to fully analyze, which wastes both the sequencing spend and the experimental effort behind it. Planning for analysis means several things. It means assessing honestly whether you have the bioinformatics capability, in people, tools, and compute, to handle the data you are about to produce, and if you do not, either building it, buying it, or reconsidering the experiment’s scale. It means evaluating the analytical ecosystem a platform offers, since vendors differ enormously in the quality of their software, pipelines, and support, and a platform with excellent analysis tools can be worth more than one with marginally better raw performance. It means budgeting for analysis, not just data generation, since the compute and personnel costs are real. And it means designing experiments around questions you can actually answer, rather than generating maximal data and hoping insight emerges, which rarely works. The labs that get the most from modern genomics are those that treat analysis as a first-class part of the experiment rather than an afterthought, and that discipline matters far more to the quality of the science than which instrument sits on the bench.
A note on this snapshot
Genomics moves faster than almost any part of the tools market, and both the technology and the competitive landscape shift continually. Treat the companies named here as a current starting point rather than a fixed ranking, and evaluate platforms against your specific scientific questions and your realistic analytical capacity. The principle that will not go out of date is that the right technology follows from the biology you want to interrogate, and that the ability to analyze what you generate matters as much as the ability to generate it.
Budget for analysis from the start
The practical discipline that most improves genomics projects is simple: budget the analysis alongside the data generation, in money, people, and time, before you commit to the experiment. If you cannot resource the analysis, scale the experiment down until you can, because unanalyzed data is worth exactly nothing and generating it wastes both the sequencing spend and the sample material behind it. Labs that plan their analysis first, and their sequencing second, consistently extract more insight per dollar than those who generate maximal data and worry about interpretation later.
Watch the consumables, not the instrument
As with most laboratory equipment, the sequencer is a one-time purchase and the reagents are forever. Consumable cost per sample, and whether you are locked into a single supplier for them, will dominate your spending over the platform’s life and should weigh heavily in the decision. Model the cost across the volume you actually expect to run, not a single experiment, and the ranking of platforms sometimes reverses entirely. The instrument price is the number vendors compete on; the consumable cost is the number that determines what you actually pay.
Talk to labs already running it
Before committing to a platform, speak to labs doing work similar to yours on the system you are considering. Ask about real-world performance on messy samples, the true cost per sample once everything is counted, how good the analytical support actually is, and whether they would choose it again. Peer experience is the most reliable information available in this market, and researchers are generally candid with one another in a way that vendor materials never are.
For the full, maintained list of life-science tools and equipment suppliers, browse the BioMed Nexus lab equipment and tools directory, and see our overview of the tools companies that power every lab.
Frequently asked questions
Who are the leading sequencing companies?
Illumina remains dominant in short-read sequencing with the broadest installed base and deepest ecosystem. Oxford Nanopore leads in long-read, real-time and portable sequencing, while PacBio offers highly accurate long reads. Element Biosciences, Ultima Genomics and Singular Genomics have emerged as credible challengers competing on cost and throughput.
Who leads in single-cell and spatial biology?
10x Genomics is the established leader in single-cell analysis, with a broad platform spanning gene expression, immune profiling and spatial approaches. NanoString pioneered spatial profiling, with Akoya Biosciences and Vizgen competing in the space. Parse Biosciences and Scale Biosciences offer combinatorial-barcoding approaches that avoid specialized instruments.
How do I choose a sequencing platform?
Start with the biological question, since the right technology follows from what you need to measure. Consider the full cost including consumables, which dominate long-run spending, weigh the ecosystem and analytical support available, and honestly assess your informatics capacity, because the bottleneck has shifted from generating data to analyzing it and generating data you cannot analyze is a costly trap.
